|
🦁
|
Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.
9 auth.
B. Glintborg,
M. Østergaard,
L. Dreyer,
N. Krogh,
U. Tarp,
M. Hansen,
...
S. Rifbjerg-Madsen,
T. Lorenzen,
M. Hetland
|
7 |
2011 |
7
🦁
|
|
🦁
|
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
24 auth.
B. Glintborg,
I. Sørensen,
A. Loft,
H. Lindegaard,
A. Linauskas,
O. Hendricks,
I. Hansen,
D. Jensen,
N. Manilo,
J. Espesen,
...
M. Klarlund,
J. Grydehøj,
S. Dieperink,
S. Kristensen,
Jimmi S Olsen,
H. Nordin,
S. Chrysidis,
Dorte Dalsgaard Pedersen,
M. Sørensen,
L. Andersen,
K. Grøn,
N. Krogh,
L. Pedersen,
M. Hetland
|
7 |
2017 |
7
🦁
|
|
🦁
|
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry
B. Glintborg,
M. Østergaard,
N. Krogh,
L. Dreyer,
Hanne Lene Kristensen,
M. Hetland
|
7 |
2010 |
7
🦁
|
|
🦁
|
Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
12 auth.
B. Glintborg,
M. Ostergaard,
N. Krogh,
M. Andersen,
U. Tarp,
A. Loft,
...
H. Lindegaard,
M. Holland-Fischer,
H. Nordin,
D. Jensen,
C. H. Olsen,
M. Hetland
|
7 |
2013 |
7
🦁
|
|
🦁
|
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry
16 auth.
B. Glintborg,
M. Østergaard,
N. Krogh,
U. Tarp,
N. Manilo,
A. Loft,
A. Hansen,
A. Schlemmer,
V. Fana,
H. Lindegaard,
...
H. Nordin,
C. Rasmussen,
L. Ejstrup,
D. Jensen,
P. M. Petersen,
M. Hetland
|
7 |
2012 |
7
🦁
|
|
🦁
|
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
24 auth.
B. Glintborg,
A. Loft,
E. Omerovic,
O. Hendricks,
A. Linauskas,
J. Espesen,
K. Danebod,
D. Jensen,
H. Nordin,
E. B. Dalgaard,
...
S. Chrysidis,
S. Kristensen,
J. Raun,
H. Lindegaard,
N. Manilo,
S. H. Jakobsen,
I. Hansen,
Dorte Dalsgaard Pedersen,
I. Sørensen,
L. Andersen,
J. Grydehøj,
F. Mehnert,
N. Krogh,
M. Hetland
|
7 |
2018 |
7
🦁
|
|
🐜
|
Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
12 auth.
H. Leffers,
M. Østergaard,
B. Glintborg,
N. Krogh,
Heidi Foged,
U. Tarp,
...
T. Lorenzen,
A. Hansen,
M. Hansen,
Martin Skov Jacobsen,
L. Dreyer,
M. Hetland
|
7 |
2011 |
7
🐜
|
|
🐬
|
The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
P. Højgaard,
B. Glintborg,
L. Kristensen,
B. Gudbjornsson,
T. Love,
L. Dreyer
|
6 |
2016 |
6
🐬
|
|
🦁
|
Drug-drug interactions among recently hospitalised patients – frequent but mostly clinically insignificant
B. Glintborg,
S. Andersen,
K. Dalhoff
|
6 |
2005 |
6
🦁
|
|
🐜
|
Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers
18 auth.
K. Hellgren,
L. Dreyer,
E. Arkema,
B. Glintborg,
L. Jacobsson,
L. Kristensen,
N. Feltelius,
M. Hetland,
J. Askling,
E. Baecklund,
...
A. Kastbom,
C. Turesson,
E. Lindqvist,
L. Jacobsson,
Lars Klareskog,
H. F. d’Elia,
S. Rantapää-Dahlqvist,
R. V. van Vollenhoven
|
6 |
2016 |
6
🐜
|
